Figures & data
Figure 1 Norgestrel: 8R,9S,10R,13S,14S,17S-13-ethyl-17-ethynyl-17-hydroxy- 1, 2, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16-dodecahydrocyclopenta[a]phenanthren-3-one.
![Figure 1 Norgestrel: 8R,9S,10R,13S,14S,17S-13-ethyl-17-ethynyl-17-hydroxy- 1, 2, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16-dodecahydrocyclopenta[a]phenanthren-3-one.](/cms/asset/cd9c21c7-5551-428d-b91c-3ee38d6a4ad7/dppa_a_3692_f0001_b.jpg)
Figure 2 The “Progestogen Tree.”
Courtesy Prof. A Genazzani, University of Pisa, Italy.
![Figure 2 The “Progestogen Tree.”Courtesy Prof. A Genazzani, University of Pisa, Italy.](/cms/asset/a7fbafa0-373c-491b-9064-f7e2831ed813/dppa_a_3692_f0002_c.jpg)
Table 1 Biological activity of different progestogens, using two different tests
Table 2 Hormonal contraceptives containing norgestrel or levonorgestrel
Figure 3 Percentage of subjects reporting no bleeding in each treatment cycle. Asterisks indicate significant difference (p = 0.05) within a cycle.
Reproduced with permission from Kwiecien M, Edelman A, Nichols MD, Jensen JF. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13.Citation83 Copyright © 2003 Elsevier.
![Figure 3 Percentage of subjects reporting no bleeding in each treatment cycle. Asterisks indicate significant difference (p = 0.05) within a cycle.Reproduced with permission from Kwiecien M, Edelman A, Nichols MD, Jensen JF. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13.Citation83 Copyright © 2003 Elsevier.](/cms/asset/e33eb521-a06b-43c3-9971-bddf3fd1fac0/dppa_a_3692_f0003_b.jpg)